Fiche publication
Date publication
juin 2026
Journal
Transplantation and cellular therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr POCHON Cécile
Tous les auteurs :
Chartral U, Fahd M, Gasperment E, Calvo C, Castelle M, Duchesne E, Gabrion A, Roudaut C, Mollet C, Ternaux B, Bouabdelli M, Schwartz E, Lefrère F, Moshous D, Barlogis V, Teyssier AC, Calmels B, Demerle C, Chateau AL, Buchbinder N, Renard C, Ouachée M, Pochon C, Gandemer V, Rialland F, Paillard C, Suarez F, Dalle JH, Bruno B, Magrin E, Neven B, Cavazzana M, Diana JS
Lien Pubmed
Résumé
TCRαβ/CD19 depletion enables mismatched and haploidentical hematopoietic stem cell transplantation (HSCT) without the use of a post-transplant alkylating agent and is particularly relevant for pediatric nonmalignant disorders. However, the complexity of graft engineering limits its availability to specialized centers. Indeed, implementing such a process and obtaining regulatory approval are resource-intensive endeavors that require sufficient patient volume. To address these limitations, we established a centralized platform for the real-time nationwide distribution of fresh TCRα/β/CD19-depleted grafts in France, prioritizing bringing the cells to the patients, rather than the patients to the cells.
Mots clés
Pediatric, graft engineering, in vitro depletion, mismatched donor, nonmalignant disorders
Référence
Transplant Cell Ther. 2026 06 13;:
